Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 33Prostatic Neoplasms 8Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pleural Effusion, Malignant 2Ovarian Neoplasms 2Neoplasms 2Mouth Neoplasms 2Lymphedema 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia 2Infertility 2Hodgkin Disease 2Fibrosis 2Carcinoma, Medullary 2Carcinoma, Intraductal, Noninfiltrating 2Anatomic Stage III Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Hemorrhage 1Unspecified Adult Solid Tumor, Protocol Specific 1Thyroid Nodule 1Thyroid Cancer, Papillary 1Stomatitis 1Somatostatinoma 1Soft Tissue Neoplasms 1

Interventions

Carboplatin 88pembrolizumab 85Paclitaxel 71Cyclophosphamide 63Capecitabine 38Doxorubicin 37Taxes 29130-nm albumin-bound paclitaxel 29Cisplatin 25Albumin-Bound Paclitaxel 22Epirubicin 21Drug Therapy 21Docetaxel 20sacituzumab govitecan 19olaparib 19camrelizumab 18atezolizumab 18Gemcitabine 17eribulin 16durvalumab 16Bevacizumab 16Radiotherapy 15toripalimab 14Specimen Handling 14Biopsy 13Everolimus 12Magnetic Resonance Spectroscopy 11apatinib 10Nivolumab 10talazoparib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Triple Negative Breast Neoplasms × High-Energy Shock Waves × Clear all
NCT05989828 2026-05-19

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

University of Southern California

Phase 1 Recruiting
20 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06635980 2025-12-12

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

Mayo Clinic

Phase 2 Recruiting
120 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
51 enrolled
Breast

Triple Negative Breast Neoplasms

NCT02276443 2025-08-01

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

M.D. Anderson Cancer Center

Phase NA Active not recruiting
798 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡